Prevention: Coronary artery calcium and polypill therapy

Nature Reviews Cardiology

Volumn 11, Issue 1, 2014, Pages 7-8

  Webster, Ruth ^a   Rodgers, Anthony ^a  

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CORONARY ARTERY CALCIUM SCORE; DRUG INDICATION; HUMAN; PATIENT SELECTION; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL;

CALCINOSIS; CALCIUM; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; POLYPHARMACY;

EID: 84891150421     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.185     Document Type: Article

References (10)

1. Wald, N. J. & Law, M. R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326, 1419 (2003).
2. Bittencourt, M. S. et al. Polypill therapy, subclinical atherosclerosis, and cardiovascular events - implications for the use of preventive pharmacotherapy: Multi-Ethnic Study of Atherosclerosis (MESA). J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.08.1640.
3. Lafeber, M. et al. The cardiovascular polypill in high-risk patients. Eur. J. Prev. Cardiol. 19, 1234-1242 (2012).
4. Yeboah, J. et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 308, 788-795 (2012).
5. Rana, J. S. et al. Comparative value of coronary artery calcium and multiple blood biomarkers for prognostication of cardiovascular events. Am. J. Cardiol. 109, 1449-1453 (2012).
6. Rozanski, A. et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing: the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J. Am. Coll. Cardiol. 57, 1622-1632 (2011).
7. Thom, S. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310, 918-929 (2013).
8. Law, M. R. & Wald, N. J. Risk factor thresholds: their existence under scrutiny. BMJ 324, 1570-1576 (2002).
9. Mendis, S. et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull. World Health Organ. 83, 820-829 (2005).
10. Morris, Z. S., Wooding, S. & Grant, J. The answer is 17 years, what is the question: understanding time lags in translational research. J. R. Soc. Med. 104, 510-520 (2011).